A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.

View/Open

Accepted version (933.8Kb)

Publication Date

2020-07

ICR Author

Lopez, Juanita

Yap, Christina

De Bono, Johann

Banerji, Udai

Author

Tiu, C

Shinde, R

Yap, C

Rao Baikady, B

Banerji, U

Minchom, AR

de Bono, JS

Lopez, JS

Type

Journal Article

Metadata

Show full item record

URL

https://repository.icr.ac.uk/handle/internal/3801

Collections

• Cancer Therapeutics
• Clinical Studies

Licenseref URL

https://www.rioxx.net/licenses/under-embargo-all-rights-reserved

Version of record

10.1016/s1470-2045(20)30339-9

Subject

Humans

Pneumonia, Viral

Coronavirus Infections

Neoplasms

Antiviral Agents

Risk Assessment

Clinical Trials, Phase I as Topic

Pandemics

United Kingdom

Betacoronavirus

Data Management

COVID-19

SARS-CoV-2

Research team

Medicine (de Bono Prostate)

Clinical Pharmacology – Adaptive Therapy

Clinical Trials & Statistics Unit

Prostate Cancer Targeted Therapy Group

Language

eng

Date accepted

2020-05-27

License start date

2020-07

Citation

The Lancet. Oncology, 2020, 21 (7), pp. 889 - 891